Verquvo (vericiguat) is used for symptomatic chronic heart failure in adults with reduced ejection fraction who are stabilized after a recent heart failure decompensation event.
Calcium channel blockers may be an important modifiable risk factor for glaucoma, possibly through a mechanism that is not related to intraocular pressure.
While the Canadian Cardiovascular Society’s lipid guidelines recommend a once in a lifetime testing of Lp(a), there are no approved agents for lowering Lp(a) levels.
